Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
NeoTCR-P1 adoptive cell therapy
nivolumab
+1 more
Locations
9
United States
City of Hope
Duarte, California, United States
University of California, Los Angeles
Los Angeles, California, United States
University of California, Irvine Medical Center
Orange, California, United States
University of California, Davis
Sacramento, California, United States
University of California, San Francisco
San Francisco, California, United States
Northwestern University Medical Center
Chicago, Illinois, United States
Start Date
July 3, 2019
Primary Completion Date
August 12, 2022
Completion Date
August 12, 2022
Last Updated
August 18, 2022
NCT04570423
NCT06144671
NCT06132828
NCT07489378
NCT06926283
NCT07177937
Lead Sponsor
PACT Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions